Key opinion leaders hold a discussion highlighting significant factors in heart failure staging.
This is a video synopsis/summary of a panel discussion involving Robert Groves, MD; Eugene E. Wright Jr, MD; Nancy Albert, PhD, CCNS, CCRN, CHFN, NE-BC, FAHA, FCCM, FHFSA, FAAN; Nihar Desai, MD, MPH; and Kelly Marie Axsom, MD. The panel discusses prevention and early identification of heart failure. Lifestyle changes like diet and medications can help curb progression of risk factors. Routine exams allow early clinical staging based on symptoms and cardiac dysfunction. Wright notes stage B is preclinical heart failure with signs of dysfunction but no symptoms. The goal is preventing progression through the stages. Patients may temporarily lack symptoms but require ongoing intense treatment. Albert explains heart failure staging is like cancer staging; you move forward but not backward. Educating patients using analogies helps them understand that the chronic nature of heart failure requires lifelong treatment. Early screening, like with annual biomarkers in primary care, allows earlier diagnosis and treatment. Artificial intelligence tools may help identify higher risk patients needing intervention. Overall there is a need for greater urgency in prevention and early identification of heart failure before symptoms arise.
Video synopsis is AI-generated and reviewed by AJMC editorial staff.
Study Highlights Key RA-ILD Risk Factors, Urges Early Screening
November 20th 2024This recent study highlights key risk factors for rheumatoid arthritis–associated interstitial lung disease (RA-ILD), emphasizing the importance of early screening to improve diagnosis and patient outcomes.
Read More
Why Right Heart Catheterization Confirming PAH Diagnosis May Be Underperformed
November 20th 2024Professional guidelines say that when pulmonary arterial hypertension (PAH) is diagnosed, right heart catheterization should be performed, but a quarter of the time, it isn’t—so investigators set out to discover why.
Read More
Insurance Insights: Dr Jason Shafrin Estimates DMD Insurance Value
July 18th 2024On this episode of Managed Care Cast, we're talking with the author of a study published in the July 2024 issue of The American Journal of Managed Care® that estimates the insurance value of novel Duchenne muscular dystrophy (DMD) treatment.
Listen
New PsA Data Highlight Long-Term Benefits of Bimekizumab
November 19th 2024A trio of abstracts presented at ACR Convergence 2024, the annual meeting of the American College of Rheumatology, bear out the benefits of bimekizumab (Bimzelx; UCB Pharma) for use against active psoriatic arthritis (PsA).
Read More